Wednesday, November 29, 2017 12:09:11 PM
Ken Kam , CONTRIBUTOR
Opinions expressed by Forbes Contributors are their own.
the best time to invest in biotech stocks is after the short-term speculators have sold.
After a very strong year, the biotech sector has suffered an 8% pullback over the past five weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro and Incyte.
Ken Kam: Your fund is up 38% this year, why do you think there is more room to grow in the sector this year?
Todd Hagopian: While the major biotechs have seen a relatively small pullback, some of the clinical stage, or one-drug companies, have pulled back extremely hard as the acquisition season has seemingly ended.
Nothing in the industry has changed, there will still be less regulation, more investment, and more innovation going forward.
The acquisitions will pick back up, and these premiums that have dissipated over the past couple months will return. This portion of the biotech sector is opening up some great bargains at the moment.
Kam: What did you look for when identifying your five biggest bargains in the sector for this article?
Hagopian: I looked at five sets of criteria:
Is the stock at least 20% off of its high?
Is the stock at least 30% off of their average target price?
Was there a revenue-based justification for pull-back?
Is an acquisition, or rumors of one, likely in the next year?
Is there is at least 50% growth potential in the next year?
Kam: Tell me about the five stocks you picked as this season’s biggest bargains?
Hagopian: The companies I chose are Alexion Pharmaceuticals (ALXN), Flexion Therapeutics (FLXN), Clovis Oncology (CLVS), Tesaro Inc (TSRO), and Incyte Corporation (INCY).
(content omitted)
Incyte
The stock is down based on buyout rumors that didn't materialize. However, this stock is part of the IDO inhibitor class, which is another growth area in immunotherapy. On top of that, INCY already has revenue of over $1B/year, offering immediate benefits to potential acquirers, beyond their valuable immunotherapy pipeline.
The bottom line is that this stock will likely be one of the next major acquisition targets in the industry, and should see $150 again over the next 12 months, offering a potential 50% return over that time period.
Kam: How are you using these five highlighted stocks in your portfolio?
Hagopian: As Biotechs have slipped over the past couple of months, I have retooled my portfolios to take advantage of what I view are the biggest bargains in the sector. These five stocks will make up approximately 35% to 45% of my portfolio moving forward.
My Take: Often, the best time to invest in biotech stocks is after the short-term speculators have sold. In the past five weeks, there have been no clinical failures with these five companies. What has changed is that the prospects for a large, quick, capital gain from a buyout decreased. Todd is confident that takeover speculation will be back and is using the pullback to buy these five stocks. I agree that the pullback has created a good entry point for those with investment horizons of more than one year.
Investing in biotech requires hours of research, combing through clinical trial data, looking at competitive drugs, analyzing the analysts, and tracking the ongoing catalysts of the stocks involved.
Todd has shown us how a good manager can apply intelligence, skill, and diligence so the outcome is not just a game of chance. He started his Biotech fund at Marketocracy in March, 2011. Since then, his returns have averaged 26.58%, which compares nicely to the S&P 500’s 12.87% return over the same period. Year-to-date, Todd’s Biotech fund is up 38.00%, versus 16.91% for the S&P, and 17.03% for the Nasdaq iShares Biotech ETF (IBB). Over the past five years, Todd has outperformed the #1 equity mutual fund manager in Morningstar's database.
Todd's Biotech fund is not a mutual fund. It is an investment option for clients of our separately managed account program. Here is Todd’s track record. For a full review of his 20+ articles on the market, please visit his profile. For information about investing with Todd, click here.
________________________________________
https://www.forbes.com/sites/kenkam/2017/11/28/biotech-pullback-makes-bargains-out-of-alexion-flexion-clovis-tesaro-and-incyte/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo#714ac7ed333d
INCY
Recent INCY News
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease • PR Newswire (US) • 09/18/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:24:17 PM
- Retifanlimab (Zynyz®) von Incyte verlängert progressionsfreies Überleben bei Patienten mit Plattenepithel-Analkarzinom (SCAC) – Datenpräsentation beim ESMO Presidential Symposium 2024 • Business Wire • 09/15/2024 10:36:00 PM
- Incyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem Stadium • Business Wire • 09/15/2024 05:34:00 AM
- INCB123667, l'inhibiteur de la CDK2 d'Incyte, montre des signes prometteurs d'activité clinique chez des patientes atteintes de tumeurs solides avancées, notamment le cancer de l'ovaire • Business Wire • 09/15/2024 05:34:00 AM
- Le rétifanlimab (Zynyz®) d’Incyte prolonge la survie sans progression chez les patients atteints de carcinome épidermoïde du canal anal (SCAC) ; des données ont été présentées lors du Symposium présidentiel de l’ESMO 2024 • Business Wire • 09/15/2024 04:48:00 AM
- Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer • Business Wire • 09/14/2024 04:45:00 PM
- Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium • Business Wire • 09/14/2024 02:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 08:06:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:17:21 PM
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/09/2024 08:30:00 PM
- Incyte présentera les résultats de la phase 3 de Retifanlimab (Zynyz®) et les données initiales du programme d'inhibiteurs de CDK2 de phase 1 à l'édition 2024 du Congrès de la Société européenne d'oncologie médicale (ESMO) • Business Wire • 08/21/2024 08:49:00 PM
- Incyte präsentiert bahnbrechende Phase 3-Ergebnisse für Retifanlimab (Zynyz®) und erste Daten aus Phase 1 des CDK2-Inhibitor-Programms auf dem Kongress der European Society of Medical Oncology (ESMO) 2024 • Business Wire • 08/21/2024 08:49:00 PM
- Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 • Business Wire • 08/21/2024 03:40:00 PM
- Incyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekannt • Business Wire • 08/16/2024 09:59:00 AM
- Incyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaire • Business Wire • 08/16/2024 09:46:00 AM
- Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma • Business Wire • 08/15/2024 08:30:00 PM
- Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD) • Business Wire • 08/15/2024 08:15:00 PM
- Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD) • Business Wire • 08/15/2024 10:26:00 AM
- Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) • Business Wire • 08/14/2024 09:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 07:37:17 PM
- Incyte to Present at Upcoming Investor Conferences • Business Wire • 08/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:39:53 PM
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/07/2024 09:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM